Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of CAPRELSA is substantial. |
Clinical Added Value
| minor |
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
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
5vLjwRXc3z27nGTK
